Creating a new generation of small molecule protease inhibitors


KalVista is advancing a pipeline of novel, small molecule plasma kallikrein inhibitors through pre-clinical and clinical development. The Company intends to develop these drug candidates as best-in-class treatments for hereditary angioedema (HAE), diabetic macular edema (DME), and other plasma kallikrein-associated diseases.

KalVista’s development programs have received grant funding from the JDRF, Innovate UK and the European Commission.

Product Portfolio

KALV pipeline October 2017